| Document |
Document Title |
|
WO/2021/167495A1 |
This invention relates to pyrimidine derivatives, having HIV replication inhibiting. The present invention provides new pyrimidine compounds, designed for the treatment and prevention of HIV-mediated diseases. The invention further relat...
|
|
WO/2021/165346A1 |
The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein X, Y, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorder...
|
|
WO/2021/163683A1 |
Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors nicotinamide N-methyltransferase (NNMT). Also disclosed are pharmaceutical compositions comprising a compound disclosed herein. Related...
|
|
WO/2021/163727A1 |
The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
|
|
WO/2021/163629A1 |
The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ULK mediated diseases, including cancer.
|
|
WO/2021/163627A1 |
The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ULK mediated diseases, including cancer.
|
|
WO/2021/161230A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2021/163633A1 |
Provided herein are methods of treating diseases, including cancer, with ULK inhibitors, both as monotherapies and in combination with other therapeutic agents.
|
|
WO/2021/157642A1 |
The present invention improves the light emission efficiency, driving voltage, and lifespan of an organic electroluminescent element using a delayed fluorescent material. A host material for a delayed fluorescent material and comprising ...
|
|
WO/2021/157593A1 |
Superior durability is demonstrated by an organic light emitting element that uses a light emitting composition including both a first compound with a PBHT value greater than 0.730 and a second compound for which ES1 is smaller than for ...
|
|
WO/2021/158516A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of IRE1α, and the treatment of IRE1α-mediated disorders.
|
|
WO/2021/155426A1 |
The present disclosure relates generally to a class of quinazoline compounds, compositions containing the same and the therapeutic use of the compounds in the treatment of cancer.
|
|
WO/2021/155764A1 |
The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
|
|
WO/2021/153786A1 |
The present invention provides a compound having an excellent control effect against pests. A compound represented by formula (1) of the present invention (in the formula, Q represents a group indicated by Q1 or a group indicated by Q2 (...
|
|
WO/2021/154904A1 |
The present disclosure encompasses solid state forms of Mavacamten, in embodiments crystalline polymorphs of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/155185A1 |
The present invention provides aminopyrimidinylaminobenzonitrile compounds that inhibit the activity of never in mitosis gene A-related kinase 2 (NEK2) and are useful in the treatment of diseases related to activity of NEK2, including ca...
|
|
WO/2021/146543A1 |
Provided herein are compounds having the following structural formula, wherein values for the variables are as described herein. Also provided are pharmaceutical compositions of the compounds, as well as methods of using the compounds to...
|
|
WO/2021/139482A1 |
The present invention belongs to the technical field of pesticides, and in particular relates to a carboxylic acid derivative-substituted imino aryl compound, a preparation method therefor, a herbicidal composition and use thereof. The c...
|
|
WO/2021/140418A1 |
Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE) by administering to a subject in need thereof, a combination of a dipeptidyl peptidase 4 (DPP-4) inhibitor and a compound of Formul...
|
|
WO/2021/139748A1 |
Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KR...
|
|
WO/2021/135517A1 |
The present application belongs to the technical field of organic materials, and specifically provided therein is an organic compound. The compound is a structure composed by using an adamantyl group as the core and by linking two nitrog...
|
|
WO/2021/136238A1 |
Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen o...
|
|
WO/2021/135183A1 |
The present application relates to the technical field of organic materials, and provides an organic compound. A novel compound for an organic electroluminescent device is obtained by bonding and combining an adamantane spiro fluorenyl g...
|
|
WO/2021/130776A1 |
The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3 methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6dihydropyrimidin-1(2H)-yl]-...
|
|
WO/2021/128764A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic device. The structure of the nitrogen-containing compound is as shown in a...
|
|
WO/2021/133509A1 |
The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and o...
|
|
WO/2021/129561A1 |
A cyano-substituted pyridine and cyano-substituted pyrimidine compound and a preparation method therefor and an application thereof, which specifically relate to a compound represented by formula (I) and an isomer, a hydrate, a solvate, ...
|
|
WO/2021/125803A1 |
The present invention relates to a novel pyrimidin derivative and a use thereof. The pyrimidin derivative has excellent MLK3 inhibitory activity and LRRK2 inhibitory activity and thus can be utilized in a pharmaceutical composition for p...
|
|
WO/2021/127071A1 |
The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compos...
|
|
WO/2021/122249A1 |
Process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is reacted with a cyclic compound comprising a cyclic compound having at least one nitrogen as ring member, bearing a substitutable hydrogen residue (cyclic...
|
|
WO/2021/123174A1 |
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cogni...
|
|
WO/2020/252581A9 |
The present application provides a colloid drug aggregate composition and methods of use and manufacture thereof. While the formation of colloidal aggregates leads to artifacts in early drug discovery, their composition makes them attrac...
|
|
WO/2021/125834A1 |
The present invention provides: a novel compound capable of improving the light-emitting efficiency, stability and lifespan of an element; an organic electrical element using same; and an electronic device thereof.
|
|
WO/2021/127273A1 |
Described herein are compounds of formulae (I), (lla) and (Mb) as prolyl hydroxylase inhibitors, HIF-lalpha stabilizers and PGK up regulators for use in treating inflammatory diseases, cancer or infections: Preferred compounds are e.g. t...
|
|
WO/2021/116709A1 |
Compounds and their Use for the Treatment of α1-Antitrypsin Deficiency The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α1...
|
|
WO/2021/114691A1 |
The present invention relates to a nitrogen-containing ring-fused compound, a preparation method therefor and a use thereof. Specifically, the present invention relates to a compound having a structure represented by formula (X), a stere...
|
|
WO/2021/118086A2 |
The present invention relates to: a novel compound having excellent carrier transport capability, luminescence capability, and thermal stability; and an organic electroluminescent device which, by comprising same in at least one organic ...
|
|
WO/2021/117846A1 |
The purpose of the present invention is to provide a compound having an inhibitory activity against a PDGF receptor kinase. The present invention includes, for example, a compound represented by formula [1] or a pharmaceutically accept...
|
|
WO/2021/116706A1 |
The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α1-antitrypsin (A1AT), and may be used in the treatment of a disease or di...
|
|
WO/2021/116050A1 |
The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/110177A1 |
Provided are a rhein derivative and antiviral use thereof, belonging to new drug development technologies. The rhein derivative has a structure as shown in general formula (I) or formula (II), and the experimental data shows that it has ...
|
|
WO/2021/113282A1 |
A method for preparing a compound of Formula 1 and compounds therefrom, comprising treating a compound of Formula 2 with a compound of Formula 3 and reacting the resulting intermediate of Formula 4 with a compound of Formula 5 (or a salt...
|
|
WO/2021/113266A1 |
Disclosed herein are methods, pharmaceutical combinations, and dosage combinations for the prevention or treatment of cognitive disorders with the administration of a therapeutic effective amount of trapidil, a derivative, a metabolite, ...
|
|
WO/2021/111311A2 |
The present invention provides novel adamantane derivatives as inhibitors of a focal adhesion kinase, pharmaceutically acceptable salts thereof, stereoisomer thereof, a hydrate or solvate thereof, and a pharmaceutical composition compris...
|
|
WO/2021/113689A1 |
The present disclosure provides SPAK/OSR inhibitors. In certain embodiments, the compounds of the disclosure can be used to treat, ameliorate, and/or prevent certain cancers in a subject.
|
|
WO/2021/113808A1 |
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating dis...
|
|
WO/2021/108683A1 |
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological proces...
|
|
WO/2021/104363A1 |
Disclosed are a composition containing an aromatic heterocyclic compound in an amorphous form, and a preparation method therefor and a use thereof. Specifically, disclosed is a composition containing a compound of formula (1) and a carri...
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102567A1 |
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors....
|
